Magnetic field and hydrogels could be used to grow new cartilage

Posted on October 28, 2020 — Jessica Jones Gupta

Using a magnetic field and hydrogels, a team of researchers in the Perelman School of Medicine have demonstrated a new possible way to rebuild complex body tissues, which could result in more lasting fixes to common injuries, such as cartilage degeneration. This research was published in Advanced Materials. Read More on Penn Today

Scout Bio advances novel gene therapy for the treatment of feline diabetes

Posted on — Jessica Jones Gupta

Scout Bio, a biotechnology company focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions, announced it has initiated two pilot clinical studies to demonstrate effectiveness of an AAV expressing a GLP-1 analog (SB-009) in treating diabetic felines. Read More

Passage Bio’s PBKR03 receives Orphan Drug and Rare Pediatric Disease designations from FDA for treatment of Krabbe Disease

Posted on — Jessica Jones Gupta

Passage Bio, Inc., a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, announced that the FDA has granted Orphan Drug and Rare Pediatric Disease  designations to PBKR03 for the treatment of Krabbe disease (Globoid Cell Leukodystrophy). Passage Bio expects to initiate a Phase 1/2 trial for PBKR03 in…

Apellis and Sobi enter collaboration for global co-development and ex-US commercialization of systemic Pegcetacoplan

Posted on October 27, 2020 — Jessica Jones Gupta

Apellis Pharmaceuticals, Inc. and Swedish Orphan Biovitrum AB  (Sobi™) announced a strategic collaboration to accelerate the advancement of systemic pegcetacoplan, a targeted C3 therapy, for the treatment of multiple rare diseases with high unmet need that impact more than 275,000 patients globally. Read More

Penn Nursing’s innovation ecosystem

Posted on — Jessica Jones Gupta

In the past five years, the school has been intentional about creating an environment that rewards risk-taking and supports failures. It’s led to story slams and accelerators and a shift to an innovation-centric mindset. Read More on Penn Today

FloBio selected as a 2020 Falling Walls finalist for Science Start-Up Breakthrough of the Year

Posted on October 22, 2020 — Jessica Jones Gupta

FloBio, an early stage medical diagnostic company announced that it was selected by Falling Walls Venture as a finalist for the Falling Walls Breakthrough of the Year in the category of Science Start-Ups.   FloBio is breaking the wall of diagnosing bleeding and thrombotic risk by pioneering a novel point-of-care diagnostic platform that enables clinicians…

PCI 101 Webinar Recording: Penn Programs to Support SEAS and Engineering Innovation

Posted on October 21, 2020 — Jessica Jones Gupta

Meet the Penn Center for Innovation and discover how PCI supports Penn engineers from ideas to licensing to startup formation. The PCI engineering licensing team will be on hand to explain how PCI works, available programs, and tips and resources for commercializing your engineering idea. This event will feature: Pamela Beatrice, Ph.D., PCI Engineering Licensing…

Webinar Recording: Latest Intellectual Property Trends for Life Sciences

Posted on October 15, 2020 — Jessica Jones Gupta

A commercialization webinar presented by the Penn Center for Innovation and Dr. Kathryn Doyle, Partner, Saul Ewing Arnstein & Lehr. This webinar overviewed the basics of intellectual property and patent protection, as well as the latest trends and legal decisions specific to IP in medicine and life sciences. This event is the second in the…

Linnaeus Therapeutics announces first patient dosed in its clinical trial of LNS8801 in combination with KEYTRUDA® (pembrolizumab) in patients with advanced cancer

Posted on October 14, 2020 — Jessica Jones Gupta

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced that it has dosed the first patient in its phase 1/2 adaptive-design clinical trial of its lead-product-candidate, LNS8801, in combination with KEYTRUDA ® (pembrolizumab) in patients who had previous clinical benefit from immune…

Edtech startup Fulphil just placed in an international pitch competition

Posted on — Jessica Jones Gupta

Penn alum Tiffany Yau started the company in 2018 after seeing that many of her classmates were leaving the Philly area after college to find the perfect venture for them to work at. She’d started to feel like Philly was her home and wondered: What if we could get them to stay here and work…